Robert McCormack - Concepedia

Author

Robert McCormack

Also Known As

Janssen Oncology, R T McCormack, R. McCormack, R. T. McCormack, ROBERT T. McCORMACK, Robert Gerber, Robert McCormack, Robert Mccormack, Robert T McCormack, Robert T. McCormack

Publications

4.2K

Citations

H-Index

Concepts

All Affiliations

Janssen (United States)Memorial Sloan Kettering Cancer Center Dana-Farber Cancer Institute National Cancer Institute Center for Medical Technology Policy

About

Robert McCormack is an author at Janssen (United States) specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	18	2.9K
2	Health Sciences	5	5	538
3	Allergy	3	3	160
4	Biochemistry	2	2	1.8K
5	Public Health	1	1	93

Robert McCormack

Publications

3.4K

Citations

H-Index

Page 1

	Year	Citations
Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids Peter Seubert, Carmen Vigo‐Pelfrey, Fred Esch, Nature Neurodegenerative DiseasesAlzheimer's DiseaseBiochemistryBioanalysisNeurochemical Biomarkers	1992	1.7K
Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials Glenn Heller, Robert McCormack, Thian Kheoh, Journal of Clinical Oncology Ctc NonzeroCancer ManagementCtc CountCtc ConversionResponse Measure	2017	229
Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer Andrés Poveda, Stanley B. Kaye, Robert McCormack, Gynecologic Oncology MedicinePathologyGynecologyTumor CellsCancer Biology	2011	176
Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer David Lorente, David Olmos, Joaquı́n Mateo, European Urology	2016	153
Circulating Tumor Cells in Peripheral Blood Samples From Patients With Increased Serum Prostate Specific Antigen: Initial Results in Early Prostate Cancer John W. Davis, Hiroyuki Nakanishi, Vikas Kumar, The Journal of Urology	2008	141
Breaking a Vicious Cycle Daniel F. Hayes, Jeff Allen, Carolyn C. Compton, Science Translational Medicine Tumor Biology ResearchCancer ManagementPathologyCancer RegistrationSocial Change	2013	121
Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. Howard I. Scher, Glenn Heller, Ana M. Molina, Journal of Clinical Oncology Ctc CountsCancer ManagementGynecologyCtc ConversionBiomarker (Medicine)	2011	113
Cardiac troponin I measurement with the ACCESS® immunoassay system: analytical and clinical performance characteristics Robert H. Christenson, Fred S. Apple, David L. Morgan, Clinical Chemistry Clinical Performance CharacteristicsDiagnosisCreatine KinaseCoronary Artery DiseaseAcute Myocardial Infarction	1998	93
Evidence of Clinical Utility: An Unmet Need in Molecular Diagnostics for Patients with Cancer David Parkinson, Robert McCormack, Susan M. Keating, Clinical Cancer Research	2014	91
Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment Martin J. Slade, Rachel Payne, Sabine Riethdorf, British Journal of Cancer Breast OncologyImmunologyCellsearch SystemPathologyTumor Biology	2008	79

Page 1